Everything below concerns Research peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
The enzyme α-carbonic anhydrase (CA) plays a vital role in regulating inorganic carbon balance within coral cells. It catalyzes two reversible reactions: the hydration of carbon dioxide (CO2) into bicarbonate (HCO−3) and a proton (H+), and the dehydration of bicarbonate back into CO2 and a proton. Through these interconversions, α-carbonic anhydrase facilitates the efficient transport and supply of dissolved inorganic carbon for both photosynthesis and calcification, maintaining the delicate equilibrium between CO2 and bicarbonate required for coral metabolic and skeletal processes. Ocean acidification poses a major threat to coral calcification by reducing the availability of carbonate ions (CO2−3), which are essential for forming calcium carbonate (CaCO3) skeletons. Under increasingly acidified conditions, corals must expend more energy to pump protons (H+) out of the calcifying space in order to maintain favorable conditions for mineral deposition. This heightened energetic demand compromises coral growth and skeletal density, resulting in weaker and more brittle structures. Consequently, coral reefs become more susceptible to physical damage from waves and storms, as well as less resilient to other environmental stressors.
other NSAIDs, corticosteroids: increased frequency of side effects, especially peptic ulcers and gastrointestinal bleeding diuretics, ACE inhibitors and other antihypertensive drugs: reduced effectiveness of these drugs with ACE inhibitors or ciclosporin, increased risk of kidney function disorders anticoagulants such as warfarin: increased risk of bleeding increased blood plasma concentrations of digoxin and methotrexate decreased plasma concentrations of lithium
Contraction is achieved by the muscle's structural unit, the muscle fiber, and by its functional unit, the motor unit. Muscle fibers are excitable cells stimulated by motor neurons. The motor unit consists of a motor neuron and the many fibers that it makes contact with. A single muscle is stimulated by many motor units. Muscle fibers are subject to depolarization by the neurotransmitter acetylcholine, released by the motor neurons at the neuromuscular junctions. In addition to the actin and myosin myofilaments in the myofibrils that make up the contractile sarcomeres, there are two other important regulatory proteins – troponin and tropomyosin, that make muscle contraction possible. These proteins are associated with actin and cooperate to prevent its interaction with myosin. Once a cell is sufficiently stimulated, the cell's sarcoplasmic reticulum releases ionic calcium (Ca2+), which then interacts with the regulatory protein troponin. Calcium-bound troponin undergoes a conformational change that leads to the movement of tropomyosin, subsequently exposing the myosin-binding sites on actin. This allows for myosin and actin ATP-dependent cross-bridge cycling and shortening of the muscle.
=== United States === In 2014, the United States Food and Drug Administration (FDA) banned the import of kratom into the U.S. due to a lack of evidence for its safety. As of 2026, kratom is illegal in ten states: Alabama, Arkansas, Connecticut, Indiana, Kansas, Louisiana, Rhode Island, Vermont, Massachusetts, and Wisconsin, and it may be outlawed by local ordinance in other states. As of early 2026, the states of Iowa, Nebraska, and South Dakota introduced bills with legislation that would ban kratom, while Iowa and Nebraska would also classify kratom as a Schedule I drug. In 2025, it both kratom and synthetic kratom were banned in the state of Massachusetts. December 2025, Ohio temporarily banned kratom-related products for 180 days, with the Ohio Board of Pharmacy moving toward a permanent ban on all forms of kratom by mid-2026. In late 2025, California Governor Gavin Newsom's administration began warning retailers that it is illegal to sell or manufacture kratom, which led to Los Angeles County banning kratom and Orange County significantly restricting kratom by banning synthetic or concentrated kratom products containing more than 2% 7-hydroxymitragynine. In 2016, kratom was banned in San Diego and Oceanside in California. In late 2017, there was consideration to make kratom a Schedule I drug. In June 2018, the US House passed the Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act. It was introduced in the Senate and referred to the Judiciary Committee, but no further action was taken.
== History == Initially released in 2002, the VADAR web server has gone through a number of revisions and updates (now in version 1.8). The latest version of the VADAR web server supports the submission of either PDB formatted files or PDB accession numbers and generates extensive tables and high quality graphs for quantitatively and qualitatively assessing protein structures determined by X-ray crystallography, NMR spectroscopy, 3D-threading or homology modelling. A separate website supports the analysis of multiple protein chains – as might be generated from a standard NMR structure determination effort.
Sources: en.wikipedia.org
When the university partially reopened, Cremer was still temporarily banned from work due to her German citizenship and would secretly visit the university in a delivery truck to continue research. Cremer was allowed to return to her work in late 1945. Prior completed the research demonstrating a novel method for measurements and qualitative and quantitative analysis in 1947. Another student of Cremer's, Roland Müller wrote his dissertation on the analytical possibilities of the gas chromatograph. Cremer was appointed director of the Physical Chemistry Institute at Innsbruck and was made a professor in 1951. Cremer began presenting Prior and Müller's work in 1947 at various scientific meetings. In 1951, three papers on Cremer's work were published in Zeitschrift für Elektrochemie, a lesser known German scientific journal. The scientific community responded to presentations and papers either negatively or not at all. Many believed that older methods were sufficient. In 1952, the British Anthony Trafford James and Archer Porter Martin and in 1953, the Czech J. Janak published reports claiming the invention of gas chromatography. Martin and his partner Richard Laurence Millington Synge won the Nobel Prize for partition chromatography, which is often credited for introducing the use of gas as a mobile phase, in 1952. All were completely ignorant of Cremer's early work. This has been attributed to the fact that Cremer spoke to the wrong people in the wrong places. Austrian analytical and micro chemists did not focus on gases, so the idea did not gain interest.
According to Neff, self-compassion consists of three main positive components and their negative counterparts: Self-Kindness versus Self-Judgment, Common Humanity versus Isolation and Mindfulness versus Over-Identification. Furthermore, there is evidence from a study by Shin & Lin suggesting specific components of self-compassion can predict specific dimensions of positive mental health (emotional, social, and psychological well-being).
The other type is in germinating seeds where it takes part in the conversion of fatty acids into sugars for the plant's growth. In this peroxisome type the enzymatic content is so different from other groups that it has an alternative name of glyoxysome. The enzymes are of the glyoxylate cycle. The plant cytoskeleton is a dynamic structure that has a scaffold of microtubules and microfilaments, but no intermediate filaments. The microtubule organizing center in plant cells is often sited underneath the cell membrane where nucleated microtubules often form sheet-like semi-parallel arrays. Plant hormones are produced by all plant cells. Different hormones act as signaling molecules to control all aspects of the plant's growth and development including embryogenesis and reproduction, and in pathogen defense.
The company was losing money in the 1960s but remained under the control of the Salmon family, descended from a founding partner. Lyons began to close some of its London tea shops and hotels; in 1963 it also merged its LEO Computers business with English Electric's computer interests to form the jointly owned English Electric LEO. In 1964, Lyons sold their half-stake; and English Electric merged the company with Marconi's computer interests to form English Electric LEO Marconi Computers. A continuing problem in the British computer industry was both lack of investment capital and competition with the much larger U.S. computer companies, such as IBM. English Electric LEO Marconi Computers merged with other companies to form International Computers Limited (ICL) which was bought by Fujitsu in 1990. In 1978, Lyons was acquired by Allied Breweries and became part of the resulting Allied Lyons. It fell on hard economic times in the late 1980s; and was sold, eventually being broken up with its ice cream and ice lolly products, which were branded as Lyons Maid, being sold to Nestlé. Other parts that were sold off included Lyons Cakes (sold to RHM and ending up as part of their Manor Bakeries subsidiary which also makes Mr Kipling's Cakes) and Ready Brek cereal (ending up being owned by Weetabix Limited). At the end of 1994, Lyons sold Lyons Biscuits to Hillsdown Holdings, which later sold it to a U.S. investment firm which subsequently sold it to British biscuit manufacturer Burton's Foods. Lyons' cake products, such as Bakewell tart and Battenberg, are owned by Premier Foods.
Sources: en.wikipedia.org
=== EC 2.7.8: Transferases for other substituted phosphate groups === EC 2.7.8.1: diacylglycerol ethanolaminephosphotransferase EC 2.7.8.2: diacylglycerol cholinephosphotransferase EC 2.7.8.3: ceramide cholinephosphotransferase EC 2.7.8.4: serine ethanolaminephosphotransferase EC 2.7.8.5: CDP-diacylglycerol—glycerol-3-phosphate 1-phosphatidyltransferase EC 2.7.8.6: undecaprenyl-phosphate galactose phosphotransferase EC 2.7.8.7: holo-[acyl-carrier-protein] synthase EC 2.7.8.8: CDP-diacylglycerol—serine O-phosphatidyltransferase EC 2.7.8.9: phosphomannan mannosephosphotransferase EC 2.7.8.10: sphingosine cholinephosphotransferase EC 2.7.8.11: CDP-diacylglycerol—inositol 3-phosphatidyltransferase EC 2.7.8.12: CDP-glycerol glycerophosphotransferase EC 2.7.8.13: phospho-N-acetylmuramoyl-pentapeptide-transferase EC 2.7.8.14: CDP-ribitol ribitolphosphotransferase EC 2.7.8.15: UDP-N-acetylglucosamine—dolichyl-phosphate N-acetylglucosaminephosphotransferase EC 2.7.8.16: deleted, now included with EC 2.7.8.2 diacylglycerol cholinephosphotransferase EC 2.7.8.17: UDP-N-acetylglucosamine—lysosomal-enzyme N-acetylglucosaminephosphotransferase EC 2.7.8.18: UDP-galactose—UDP-N-acetylglucosamine galactose phosphotransferase EC 2.7.8.19: UDP-glucose—glycoprotein glucose phosphotransferase EC 2.7.8.20: phosphatidylglycerol—membrane-oligosaccharide glycerophosphotransferase EC 2.7.8.21: membrane-oligosaccharide glycerophosphotransferase EC 2.7.8.22: 1-alkenyl-2-acylglycerol choline phosphotransferase EC 2.7.8.23: carboxyvinyl-carboxyphosphonate phosphorylmutase EC 2.7.8.24: CDP-diacylglycerol—choline O-phosphatidyltransferase EC 2.7.8.25: Now EC 2.4.2.52, triphosphoribosyl-dephospho-CoA synthase EC 2.7.8.26: adenosylcobinamide-GDP ribazoletransferase EC 2.7.8.27: sphingomyelin synthase EC 2.7.8.28: 2-phospho-L-lactate transferase EC 2.7.8.29: L-serine-phosphatidylethanolamine phosphatidyltransferase EC 2.7.8.30: Now EC 2.4.2.53, undecaprenyl-phosphate 4-deoxy-4-formamido-L-arabinose transferase EC 2.7.8.31: undecaprenyl-phosphate glucose phosphotransferase EC 2.7.8.32: 3-O-α-D-mannopyranosyl-α-D-mannopyranose xylosylphosphotransferase EC 2.7.8.33: UDP-N-acetylglucosamine—undecaprenyl-phosphate N-acetylglucosaminephosphotransferase EC 2.7.8.34: CDP-L-myo-inositol myo-inositolphosphotransferase EC 2.7.8.35: UDP-N-acetylglucosamine—decaprenyl-phosphate N-acetylglucosaminephosphotransferase EC 2.7.8.36: undecaprenyl phosphate N,N′-diacetylbacillosamine 1-phosphate transferase EC 2.7.8.37: α-D-ribose 1-methylphosphonate 5-triphosphate synthase EC 2.7.8.38: archaetidylserine synthase EC 2.7.8.39: archaetidylinositol phosphate synthase EC 2.7.8.40: UDP-N-acetylgalactosamine-undecaprenyl-phosphate N-acetylgalactosaminephosphotransferase EC 2.7.8.41: cardiolipin synthase (CMP-forming) EC 2.7.8.42: Kdo2-lipid A phosphoethanolamine 7′′-transferase EC 2.7.8.43: lipid A phosphoethanolamine transferase EC 2.7.8.44: teichoic acid glycerol-phosphate primase EC 2.7.8.45: teichoic acid glycerol-phosphate transferase EC 2.7.8.46: teichoic acid ribitol-phosphate primase EC 2.7.8.47: teichoic acid ribitol-phosphate polymerase
In series 4, Henry enters politics as a Conservative MP but loses his seat to Jennifer Bevan in a Labour landslide, after which he falls into severe depression that strains his marriage to Yasmin. On his 40th birthday—mirroring the age at which his father committed suicide—he nearly takes his own life but stops himself and accepts an offer from Whitney Halberstram to become CEO of fintech startup Tender. His early tenure includes overseeing Tender’s merger with Austrian bank IBN Bauer and the launch of its banking app. While in Austria, Yasmin arranges a threesome involving Henry and assistant Hayley Clay, which Hayley later reveals was secretly recorded. Henry grows closer to Whitney, who develops a sexual fixation on him and takes him on a bender at a gay club, threatening his sobriety. After Harper exposes Tender’s fraudulent practices, the company’s stock drops 28%. Henry fires the firm’s auditor and confronts Whitney, who gives him a handwritten letter confirming his criminal exposure. Rather than go to authorities, Henry supports Whitney’s attempted takeover of Pierpoint to delay scrutiny, unaware that Yasmin is working with Norton to shift public blame onto Henry and the Labour government. He later learns the takeover was a sham and that he never held a stake in Pierpoint. After Yasmin tells him she no longer loves him and asks for a divorce, Whitney urges Henry to flee to Lithuania, revealing Russian state intelligence is involved in Tender.
== Composition == According to a 2007 study published in the Journal of Ethnopharmacology, the composition of cannabis tea is affected by criteria including, but not limited to, the duration of time over which the cannabis is steeped, the volume of tea prepared, and the period of time for which the tea is stored before consumption. The study mentions the ways in which levels of THC and THCA impact variability of composition by changing the bioactivity of the beverage. Therefore, cannabis teas that include less bioactive cannabinoids, "based on HPLC peak area" will demonstrate varying compositions.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.